Nail Paksoy
- 4.5 Bom • 2 avaliações
- 14 anos de experiência
- acreditações:
- Turquia, Istambul, Medipol Bahçelievler Hospital
PROFESSIONAL EXPERIENCE2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, TurkeyINTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
- Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Role: Subinvestigator
2. PFİZER
- Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
- Role: Subinvestigator
3. RECITE - AMGEN
- Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
- Role: Subinvestigator
4. NAVIGATE - BAYER
- Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
- Role: Subinvestigator
5. RUBY - Tesaro (PRA)
- Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
- Role: Subinvestigator
6. ENGOT-ov43/GOG-3036 - MSD
- Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
- Role: Subinvestigator
7. ASTRA ZENECA
- Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
- Role: Subinvestigator
8. ROSY-O - ASTRA ZENECA
- Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
- Role: Subinvestigator
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
- Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
- Journal: Medicine, 102(5)
Carboplatin Desensitization in Ovarian Carcinoma
- Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
- Journal: Medicine, 101(45), e31726
High-Dose Chemotherapy for Ewing’s Sarcoma
- Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
- Journal: Medicine, 101(49), e32213
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
- Authors: Paksoy, Nail, et al.
- Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221
Crizotinib Efficacy in NSCLC with MET Alterations
- Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
- Journal: Medicine, 101(50), e32368
Clinicopathological Features in ALK Mutant NSCLC
- Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
- Journal: Medicine, 101(34)
PSMA-Based Tumor Burden in Prostate Cancer
- Authors: HAS SIMSEK, Duygu, et al.
- Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690
Atezolizumab in Metastatic Urothelial Carcinoma
- Authors: TURAL, Deniz, et al.
- Journal: European Urology Focus, 2021, 7.5: 1061-1066
Pulmonary Sarcomatoid Carcinoma
- Authors: FERHATOGLU, Ferhat, et al.
- Journal: Oncology Research and Treatment, 2021, 44.11: 590-601
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
- Authors: TURAL, Deniz, et al.
- Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
- Authors: GÜRBÜZ, Mustafa, et al.
- Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
- Authors: AY, Seval, et al.
- Journal: Journal of Chemotherapy, 2022, 1-7
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
- Authors: CIL, Ibrahim, et al.
- Journal: Tumori Journal, 2022, 108.1: 19-25
Real-Life Efficacy of Osimertinib in Advanced NSCLC
- Authors: HIZAL, Mutlu, et al.
- Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508
ALK-Positive Cells Percentage and Alectinib Efficacy
- Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
- Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148
Real-World Data on Alectinib in ALK-Positive NSCLC
- Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
- Journal: Future Oncology, 18(23), 2573-2582
Prognostic Factors in Metastatic RCC with T790M Mutation
- Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
- Journal: Journal of Cancer Research and Therapeutics
FLOT Regimen in Metastatic Gastric Cancer
- Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
- Journal: Journal of Cancer Research and Therapeutics
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
- Authors: DEMIR, Semra, et al.
- Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
- Authors: ÖZDEMIR, Seçil Kepil, et al.
- Journal: Allergy, 2019, 74.6: 1187-1190
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
- Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
- Journal: The Oncologist, oyad257
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
- Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
- Journal: BMC cancer, 23(1), 192
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
- Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
- Journal: Scientific Reports, 13(1), 8779
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
- Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
- Journal: Journal of Cancer Research and Clinical Oncology, 1-9
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
- Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
- Journal: European Journal of Breast Health, 19(2), 128
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
- Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
- Journal: Future Oncology, 19(10), 727-736
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
- Authors: Dogan, I., Paksoy, N., & Basaran, M.
- Journal: Journal of Cancer Research and Therapeutics
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
- Authors: Dogan, I., Paksoy, N., & Basaran, M.
- Journal: Journal of Cancer Research and Therapeutics
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
- Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
- Journal: Journal of Cancer Research and Therapeutics
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
- Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
- Journal: Journal of Cancer Research and Therapeutics
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
- Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
- Journal: [Not specified]
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
- Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
- Journal: Medicine, 102(39), e35383
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
- Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
- Journal: Medicine, 102(41), e35245
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
- Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
- Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
- Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
- Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
- Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
- Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
- Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
- Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
- Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
- Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)
- Leia mais